Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients

Journal of Nuclear Medicine

Volumn 39, Issue 3, 1998, Pages 484-489

  Loh, Angela ^b   Sgouros, George ^a   O'Donoghue, Joseph A ^b   Deland, Devie ^b   Puri, Dennis ^b   Capitelli, Peter ^b   Humm, John L ^b   Larson, Steven M ^b   Old, Lloyd J ^b   Divgi, Chaitanya R ^b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

Antibody; Modeling; Pharmacokinetics; Radioimmunotherapy; Treatment planning

Indexed keywords

ANTIBODY; IODINE 131;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLEARANCE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; DRUG DISTRIBUTION; FEMALE; HUMAN; KIDNEY CARCINOMA; MALE; MATHEMATICAL MODEL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; FEMALE; HUMANS; IODINE RADIOISOTOPES; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; MODELS, THEORETICAL; RADIOIMMUNOTHERAPY; TISSUE DISTRIBUTION;

EID: 0031905826     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Schlom J, Molinolo A, Simpson JF, et al. Advantage of dose fractionation in monoclonal antibody-targeted radioimmunotherapy. J Natl Cancer Inst 1990;82:763-771.
2. 131I-labeled monoclonal antibody CC49. Cancer Res 1995;55(suppl):5881s-5887s.
3. 131I-Lym-1. Cancer Res 1990; 58(suppl):1014s-1016s.
4. Meredith RF, Khazaeli MB, Liu T, et al. Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer. J Nucl Med 1992;33:1648-1653.
5. 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res 1995;55(suppl):5916s-5920s.
6. Koizumi K, DeNardo GL, DeNardo SJ, et al. Multicompartmental analysis of the kinetics of radioiodinated monoclonal antibody in patients with cancer. J Nucl Med 1986;27:1243-1254.
7. Eger RR, Covell DG, Carrasquillo JA, et al. Kinetic model for the biodistribution of an indium-111-labeled monoclonal antibody in humans. Cancer Res 1987;47:3328-3336.
8. 2, and Fab′ in mice. Cancer Res 1986;46:3969-3978.
9. Rescigno A, Bushe H, Brill AB, Rusckowski M, Griffin TW, Hnatowich DJ. Pharmacokinetic modeling of radiolabeled antibody distribution in man. Am J Physiol Imaging 1990;5:141-150.
10. Yuan F, Baxter LT, Jain RK. Pharmacokinetic analysis of two-step approaches using bifunctional and enzyme-conjugated antibodies. Cancer Res 1991;51:3119-3130.
11. Baxter LT, Yuan F, Jain RK Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: comparison with experimental data. Cancer Res 1992;52:5838-5844.
12. van Osdol WW, Sung C, Dedrick RL, Weinstein JN. A distributed pharmacokinetic model of two-step imaging and treatment protocols: application to streptavidin-conjugated monoclonal antibodies and radiolabeled biotin. J Nucl Med 1993;34:1552-1564.
13. Mulshine JL, Shuke N, Daghighian F, et al. The correct dose: pharmacologically guided end point for anti-growth factor therapy. Cancer Res 1992;(suppl):2743s-2746s.
14. Sgouros G, Graham MC, Divgi CR, Larson SM, Scheinberg DA. Modeling and dosimetry of monoclonal antibody M195 (anti-CD33) in acute myelogenous leukemia. J Nucl Med 1993;34:422-430.
15. Sgouros G, Scheinberg DA. The treatment of leukemia with radiolabeled monoclonal antibodies. In: Rosen ST, Kuzel TM, eds. Immunoconjuage therapy of hematologic malignancies. Norwell, MA: Kluwer Academic; 1993:23-64.
16. Sgouros G. Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis. J Nucl Med 1992;33:2167-2179.
17. Hartmann C, Bloedow DC, Dienhart DG, et al. A pharmacokinetic model describing the removal of circulating radiolabeled antibody by extracorporeal immunoadsorption. J Pharmacokin Biopharma 1991;19:385-403.
18. Norrgren K, Strand S, Ingvar C. Contrast enhancement in RII and modification of the therapeutic ratio in RIT: a theoretical evaluation of simulated extracorporeal immunoadsorption. Antibody Immunocon Radiopharm 1992;5:61-73.
19. Oosterwijk E, Bander NH, Divgi CR, et al. Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. J Clin Oncol 1993;11:738-750.
20. Macey DJ, Grant EJ, Bayouth JE, et al. Improved conjugate view quantitation of iodine-131 by subtraction of scatter and septal penetration events with a triple energy window method. Med Phys 1995;22:1637-1643.
21. Berman M, Weiss MF. SAAM manual (DHEW Publication no. (NIH) 78-810). Washington, D.C.: U.S. Government Printing Office; 1978.
22. Foster DM, Boston RC, Jacquez JA, Zech LA. The SAAM tutorials: an introduction to using conversational SAAM, version 30. Seattle, WA: Resource Facility for Kinetic Analysis; 1989.
23. International Commission on Radiological Protection. Report of the task group on reference man (Publication no. 23). New York: Pergamon Press; 1975.
24. Zanzonico PB, Bigler RE, Primus FJ, et al. A compartmental modeling approach to the radiation dosimetry of radiolabeled antibody. In: Schlafke-Stelson AT, Watson EE, eds. In: Proceedings of the Fourth International Dosimetry Symposium. Oak Ridge, TN; 1985:421-445.
25. 131I plasma proteins in the rat. Am J Physiol 1959;197:423-431.
26. Strand SE, Zanzonico P, Johnson TK. Pharmacokinetic modeling. Med Phys 1993;20: 497-611.
27. Caron PC, Jurcic JG, Scott AM, et al. A phase I B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood 1994;83:1760-1768.
28. Yokota T, Milenic DE, Whitlow M, Schlom J. Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 1992;52:3402-3408.